Practical implication
Healthcare providers and compounding facilities should implement the new temporary policies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act to ensure compliance and access to essential nutrition products.
On September 4, 2026, the FDA announced immediate guidance to support the compounding of certain starter parenteral nutrition products to prevent supply disruptions. This action aims to ensure continued access for vulnerable patients, particularly premature and critically ill newborns who require nutrition via IV due to their inability to feed orally. The guidance details temporary regulatory and enforcement priorities for state-licensed pharmacies and outsourcing facilities compounding these essential drugs.
What changed: The FDA issued immediately-in-effect guidance detailing temporary regulatory and enforcement priorities regarding compounded starter parenteral nutrition drug products for neonates, addressing supply gap concerns.
Why it matters: This regulatory action is crucial as it seeks to maintain access to life-saving nutrition for vulnerable newborns during a potential supply disruption, ensuring patient care is not compromised.
Practical implication: Healthcare providers and compounding facilities should implement the new temporary policies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act to ensure compliance and access to essential nutrition products.
View original source
- Source: FDA - What's New Drugs RSS
- Published at source: 2026-09-04T00:00:00.000Z
- Discovered by monitor: 2026-09-04T21:35:40.428Z
Published from the regulator source ingestion pipeline after PV impact triage.
